On a GAAP basis, net loss for the fourth quarter 2011 was $49.8 million, or a loss of $2.03 per diluted share, compared to a net loss of $4.8 million, or a loss of $0.20 per diluted share, for the fourth quarter 2010. Excluding expenses related to restructuring and other nonrecurring charges, adjusted net loss for the fourth quarter 2011 was $1.1 million, or a loss of $0.04 per diluted share. This compares to an adjusted net loss of $3.2 million, or a loss of $0.13 per diluted share, for the fourth quarter 2010, which also excludes the impact of restructuring and other nonrecurring charges.
Full Year 2011 Financial Results
Revenue for the twelve months ended December 31, 2011 was $119.0 million, a decrease of 0.8% compared to $119.9 million reported in the prior year. Patient revenue decreased $13.1 million due to slightly lower MCOT TM volume in the second half due to lower patient census in physicians’ offices as well as lower reimbursement rates, partially offset by an increase in event and Holter volumes. Substantially offsetting the patient revenue decline was the addition of Biotel, which generated revenue of $12.2 million. For the twelve months ended December 31, 2011, patient revenue was comprised of 36% Medicare and 64% commercial, and patient volume was comprised of 51% Medicare and 49% commercial.
Gross profit for the twelve months ended December 31, 2011 decreased to $69.9 million, or 58.8% of revenue, compared to $72.4 million, or 60.4% of revenue, in the prior year. The decline in gross profit percentage was related to the addition of the lower margin Biotel business.On a GAAP basis, operating expenses for the twelve months ended December 31, 2011 were $131.3 million, an increase of 42.5% compared to $92.1 million in the prior year. This increase was driven by a goodwill impairment charge of $46.0 million. Operating expenses on an adjusted basis declined by 8.6% compared to the prior year, excluding $53.5 million for the twelve months ended December 31, 2011 and $7.1 million for the twelve months ended December 31, 2010 related to restructuring and other nonrecurring charges. The decrease in operating expenses was substantially driven by a reduction in bad debt expense, as well as a reduction in outside services and professional fees. These reductions were partially offset by the addition of Biotel’s operating expenditures.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV